Daily BriefsJapan

Daily Brief Japan: ASICS Corp, TIS, Money Forward , Honda Motor, Vega Corp, TSE Tokyo Price Index TOPIX, Hisamitsu Pharmaceutical Co, Neos Corp and more

In today’s briefing:

  • Asics (7936 JP): Huge Forecast Revision to Offset Limited Passive Buying
  • Japan – Yet Another Big Round of Passive Selling Expected in August
  • Money Forward (3994) | Metronomic Growth
  • Honda Motor Placement – Past Large Deals Analysis – Could Do with a Bit More Correction
  • Vega’s Lowya Expanding Omnichannel to Grow Audience
  • Determine Whether Shareholder Return Is a Temporary Measure or a Shift to Value-Creating Management
  • Hisamitsu Pharmaceutical (4530 JP): Mixed Performance in Q1FY25; No Change in FY25 Guidance
  • Neos Corp (3627 JP): Q1 FY02/25 flash update


Asics (7936 JP): Huge Forecast Revision to Offset Limited Passive Buying

By Brian Freitas

  • 15 shareholders are looking to sell between 73.9-85m shares (US$1.2bn-US$1.38bn) of ASICS Corp (7936 JP) in a secondary offering that will likely be priced on 23 July.
  • ASICS Corp (7936 JP) has also announced a huge upward revision to its sales and profit forecasts with EPS expected to increase 61% from earlier estimates.
  • Passive buying will be extremely limited in the short-term with the downward pressure offset to a large extent by the sales and earnings revisions.

Japan – Yet Another Big Round of Passive Selling Expected in August

By Brian Freitas

  • There are a bunch of stocks that have underperformed the Nikkei 225 (NKY INDEX) and their peers and could be deleted from global passive portfolios in August.
  • The deletion from passive portfolios will lead to a liquidity event at the end of August where passive trackers will need to sell multiple days of ADV.
  • Shorts have been built up on all the stocks over the last few months and the extent of the positioning varies across stocks.

Money Forward (3994) | Metronomic Growth

By Mark Chadwick

  • Money Forward released Q2 results post market close on Friday. Revenue growth of +41% YoY beat our estimates by 7%.
  • We highlight continued solid financial metrics supported by growth in SaaS ARR and in particular mid-sized corporate growth.
  • No change to our bullish long-term view on the company. Stock has run up around 11% ahead of earnings but we see further 20%+ upside from here. 

Honda Motor Placement – Past Large Deals Analysis – Could Do with a Bit More Correction

By Sumeet Singh

  • A group of shareholders aims to raise up to US$3.2bn via selling around 5% of Honda Motor (7267 JP).
  • The possibility of such a selldown was flagged by Reuters prior to the deal launch.
  • In our earlier note, we spoke about the deal dynamics. In this note, we talk about the updates since then.

Vega’s Lowya Expanding Omnichannel to Grow Audience

By Michael Causton

  • Lowya began as an online furniture retailer and is still one of the largest in e-commerce, but limited brand awareness has held it back and sales fell last year. 
  • Vega Corporation, Lowya’s parent, is now expanding physical stores and offering omnichannel solutions to fix the problem.
  • This makes sense in a market where stores remain preeminent and are likely to remain so.

Determine Whether Shareholder Return Is a Temporary Measure or a Shift to Value-Creating Management

By Aki Matsumoto

  • The dissolution of cross-shareholdings and changing environment in which foreign ownership has risen to 30% have changed the view of activist investors. TSE is one such example of big change.
  • It’s convenient that activist investors can use “TSE requested” language that is both easily understood and undeniable by the company when communicating with the portfolio company to improve its issues.
  • We must determine whether this is a temporary return to shareholders until the activist investors are removed from the shareholder list, or a shift to value-creating management.

Hisamitsu Pharmaceutical (4530 JP): Mixed Performance in Q1FY25; No Change in FY25 Guidance

By Tina Banerjee

  • Hisamitsu Pharmaceutical Co (4530 JP) has reported double-digit growth in revenue and net profit in Q1FY25. However, operating profit decreased 5% YoY due to higher expenses.  
  • Topline growth was mainly driven by Salonpas, which was named the world’s no. 1 OTC topical analgesic patch band for the eighth consecutive year.  
  • The company reiterated FY25 guidance of 7% revenue growth and low double-digit operating and net profit growth, as an increase in operating profit is expected for the full-year as planned.

Neos Corp (3627 JP): Q1 FY02/25 flash update

By Shared Research

  • In Q1 FY02/25, TECMIRA reported revenue of JPY2.8bn (+53.7% YoY), operating loss of JPY42mn, and net loss of JPY31mn.
  • Revenue growth was driven by strong sales of new Nintendo Switch software and first-time consolidation of Wellmira.
  • AI & Cloud segment saw significant revenue increase due to AI chatbot services, while IoT & Devices segment grew 2.6x YoY.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars